Nachrichten zur AstraZeneca PLC Aktie

Astrazeneca: Wichtiges Medikament erreicht Ziele in Lungenkrebsstudie

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in einer abschließenden klinischen Studie (Phase-III) mit Lungenkrebs-Patienten…

Imfinzi improved OS & PFS in limited-stage SCLC

05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…

AstraZenecas (AZN) Imfinzi Improves Survival in SCLC Study

AstraZenecas (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase…

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

FDA approves AstraZenecas (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck…

Total Voting Rights

2 April 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

FDA accepts Dato-DXd BLA for breast cancer

2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…

AstraZenecas (AZN) Rare Blood Disorder Drug Gets FDA Nod

FDA approves AstraZenecas (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult…

AstraZeneca gets FDA approval for PNH drug Voydeya

…

DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9500 Pence…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation…

AstraZeneca CEO Soriot on Pharmaceuticals in China

AstraZeneca CEO Pascal Soriot discusses the drugmaker’s business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships…

Astra, Pfizer Boost China Bets Despite US Drive to Decouple

The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…

AstraZenecas (AZN) Ultomiris Gets FDA Nod for New Indication

FDA approves AstraZenecas (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of…

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…

What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals

…

Fusion Pharmaceuticals Stock Soars. It’s Being Acquired by AstraZeneca in $2.4 Billion Deal.

…

Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover

The company is working on radiopharmaceuticals treatments for cancer.…

AstraZeneca: Der Pharma-Riese bleibt in Sachen M&A sehr aktiv - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting

AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…

AstraZeneca übernimmt Krebsspezialisten Fusion Pharmaceuticals

Frankfurt (Reuters) - Der Pharmakonzern AstraZeneca verstärkt sich im Geschäft mit Krebsarzneien mit einem Milliardenzukauf.

Für rund zwei Milliarden Dollar…

Pharmakonzern Astrazeneca will Onkologie-Spezialisten Fusion übernehmen

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca will den kanadischen Krebsspezialisten Fusion Pharmaceuticals übernehmen. Dabei…

AstraZeneca will buy Fusion Pharmaceuticals for ~$2B

…

AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion

AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer…

AstraZeneca to buy Fusion Pharma for $2 billion in cash By Reuters

AstraZeneca to buy Fusion Pharma for $2 billion in cash…

AstraZeneca to acquire Fusion

19 March 2024 AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer Includes actinium-based clinical-stage radioconjugate targeting PSMA…

AstraZeneca caps inhaler costs at $35 for eligible US patients By Investing.com

AstraZeneca caps inhaler costs at $35 for eligible US patients…

AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month By Reuters

AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month…

Kommunen fordern "Atempause" bei Flüchtlingen - TE-Wecker am 18. März 2024

Kommunen fordern "Atempause" bei Flüchtlingen ++ EU schließt 7,4-Milliarden-Flüchtingsdeal mit Ägypten ++ Teilurteil in Corona-Prozess gegen AstraZeneca erwartet ++ neue…

Pharma Stock Roundup: AZNs New Acquisition, FDA Updates for NVO & LLY and More

AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lillys (LLY) donanemab and approves…

AstraZeneca: Milliardenschwerer Deal verkündet - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come

A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca…

AstraZeneca: Rating gesenkt

Frankfurt (www.aktiencheck.de) - Rating-Update: Die Analysten von ODDO BHF stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG,…

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration…

AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio By Reuters

AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio…

AstraZeneca to acquire Amolyt

14 March, 2024 AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline Amolyt development portfolio includes Phase III asset with potential to address…

AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latters…

Global Recombinant Vaccine Market Size To Exceed USD 24.9 Billion By 2032 | CAGR of 11.75%

The Global Recombinant Vaccine Market Size was Valued at USD 8.2 Billion in 2023 and the Worldwide Recombinant Vaccine Market…

Acinetobacter Pneumonia Therapeutics Market to Reach USD 927.1 Million to 2031

Companies covered in this study are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson…

AstraZeneca pledges £650M in UK investments to boost vaccine capabilities, expand near HQ

AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing…

AstraZeneca to invest 650 million pounds in UK to boost pandemic preparedness By Reuters

AstraZeneca to invest 650 million pounds in UK to boost pandemic preparedness…

AstraZeneca: Das Jahr 2024 immer noch "relativ katalysatorarm" - Aktienanalyse

New York (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von Guggenheim Securities: Die Analysten von Guggenheim Securities stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292,…

EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

4 March 2024 Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative…

Judge rejects AstraZeneca’s challenge to Medicare drug price negotiations

U.S. District Judge Colm Connollys decision comes one day before manufacturers have to respond to Medicares initial price offers for…

Total Voting Rights

1 March 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…